GENERATION OF MCHERRYBODY: AN ANTI-TRANSFERRIN RECEPTOR ANTIBODY VARIABLE FRAGMENT LINKED BY THE MCHERRY FLUORESCENT PROTEIN

被引:0
|
作者
Kusharyoto, Wien [1 ]
Andriani, Dian [1 ]
Handayani, Ira [1 ]
机构
[1] Indonesian Inst Sci LIPI, Res Ctr Biotechnol, Lab Appl Genet Engn & Prot Design, Cibinong Sci Ctr, Jalan Raya Bogor KM 46, Bogor 16911, Indonesia
关键词
antibody variable fragment; fluorescent protein; molecular design; mCherry; transferrin receptor;
D O I
暂无
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
A facile generation of a recombinant antibody fragment with intrinsic fluorescent properties of the monomeric mCherry fluorescent protein is described. The so-called mCherryBody was designed based on the structure model of the variable fragment of anti-transferrin receptor antibody LUCA31 and the X-ray crystallographic structure of the mCherry protein. mCherryBody was constructed to retain optimal spatial geometry between the C-and N-termini of the antibody light-chain (V-L) and heavy-chain (V-H) by mimicking the domains interface pairing in antibody Fab fragments and incorporation of the mCherry fluorescent protein as a bridging scaffold. The gene encoding the chimeric protein was cloned into the pJExpress414 expression vector, expressed and secreted into the periplasm of Escherichia coli NiCo21(DE3) for assembly and disulphide bond formation. Based on its amino acid sequence, mCherryBody was predicted to have a molecular weight of 51.46 kDa. The modular assembly used in the generation of mCherryBody may permit the interchange of binding sites and of fluorescent proteins to create robust panels of coloured antibody fragments. Thus, the mCherryBody platform facilitates rapid generation of colored single-chain variable fragment (scFv) chimeras that could be used for screening of antibodies against cell surface markers or receptors.
引用
收藏
页码:55 / 62
页数:8
相关论文
共 50 条
  • [31] Genetically engineered brain drug delivery vectors:: cloning, expression and in vivo application of an anti-transferrin receptor single chain antibody-streptavidin fusion gene and protein
    Li, JY
    Sugimura, K
    Boado, RJ
    Lee, HJ
    Zhang, C
    Duebel, S
    Pardridge, WM
    PROTEIN ENGINEERING, 1999, 12 (09): : 787 - 796
  • [32] RADIOIMMUNOCHEMICAL MEASUREMENT OF THE TRANSFERRIN RECEPTOR PROTEIN IN HUMAN RETICULOCYTE MEMBRANES WITH A SPECIFIC ANTI-RECEPTOR ANTIBODY
    SHINDELMAN, JE
    ENNS, CA
    TONIK, SE
    SUSSMAN, HH
    CLINICAL RESEARCH, 1981, 29 (02): : A348 - A348
  • [33] EVALUATION OF PROTEIN-N-(2-HYDROXYPROPYL)METHACRYLAMIDE COPOLYMER CONJUGATES AS TARGETABLE DRUG CARRIERS .1. BINDING, PINOCYTIC UPTAKE AND INTRACELLULAR-DISTRIBUTION OF TRANSFERRIN AND ANTI-TRANSFERRIN RECEPTOR ANTIBODY CONJUGATES
    FLANAGAN, PA
    KOPECKOVA, P
    KOPECEK, J
    DUNCAN, R
    BIOCHIMICA ET BIOPHYSICA ACTA, 1989, 993 (01) : 83 - 91
  • [34] Evaluation of Efficacy of Radioimmunotherapy with 90Y- Labeled Fully Human Anti-Transferrin Receptor Monoclonal Antibody in Pancreatic Cancer Mouse Models
    Sugyo, Aya
    Tsuji, Atsushi B.
    Sudo, Hitomi
    Okada, Maki
    Koizumi, Mitsuru
    Satoh, Hirokazu
    Kurosawa, Gene
    Kurosawa, Yoshikazu
    Saga, Tsuneo
    PLOS ONE, 2015, 10 (04):
  • [35] Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells
    Yi Hong
    Juan Yang
    Xin Shen
    Huifen Zhu
    Xiaoxu Sun
    Xue Wen
    Jing Bian
    Heyu Hu
    Lu Yuan
    Juan Tao
    Ping Lei
    Guanxin Shen
    Cancer Immunology, Immunotherapy, 2013, 62 : 447 - 454
  • [36] Sinomenine hydrochloride enhancement of the inhibitory effects of anti-transferrin receptor antibody-dependent on the COX-2 pathway in human hepatoma cells
    Hong, Yi
    Yang, Juan
    Shen, Xin
    Zhu, Huifen
    Sun, Xiaoxu
    Wen, Xue
    Bian, Jing
    Hu, Heyu
    Yuan, Lu
    Tao, Juan
    Lei, Ping
    Shen, Guanxin
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2013, 62 (03) : 447 - 454
  • [37] Tumor-specific targeting of wtp53 by anti-transferrin receptor single chain antibody: a new therapeutic strategy for cancer treatment.
    Xu, L
    Alexander, WA
    Tang, WH
    Huang, CC
    Cheng, EH
    CLINICAL CANCER RESEARCH, 1999, 5 : 3748S - 3748S
  • [38] A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions
    Neiveyans, Madeline
    Melhem, Rana
    Arnoult, Christophe
    Bourquard, Thomas
    Jarlier, Marta
    Busson, Muriel
    Laroche, Adrien
    Cerutti, Martine
    Pugniere, Martine
    Ternant, David
    Gaborit, Nadege
    Chardes, Thierry
    Poupon, Anne
    Gouilleux-Gruart, Valerie
    Pelegrin, Andre
    Poul, Marie-Alix
    MABS, 2019, 11 (03) : 593 - 605
  • [39] An anti-transferrin receptor-avidin fusion protein exhibits both strong proapoptotic activity and the ability to deliver various molecules into cancer cells
    Ng, PP
    Dela Cruz, JS
    Sorour, DN
    Stinebaugh, JM
    Shin, SU
    Shin, DS
    Morrison, SL
    Penichet, ML
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2002, 99 (16) : 10706 - 10711
  • [40] Targeting anti-transferrin receptor antibody (OX26) and OX26-conjugated liposomes to brain capillary endothelial cells using in situ perfusion
    Gosk, T
    Vermehren, C
    Storm, G
    Moos, T
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 2004, 24 (11): : 1193 - 1204